A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β-Cells.
Teresa BuenaventuraNisha KandaPhoebe C DouzenisBen JonesStephen R BloomPauline ChabosseauIvan R CorrêaDomenico BoscoLorenzo PiemontiPiero MarchettiPaul R JohnsonAndrew Mark James ShapiroGuy A RutterAlejandra TomasPublished in: Diabetes (2017)
The glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) is a key target for type 2 diabetes (T2D) treatment. Because endocytic trafficking of agonist-bound receptors is one of the most important routes for regulation of receptor signaling, a better understanding of this process may facilitate the development of new T2D therapeutic strategies. Here, we screened 29 proteins with known functions in G protein-coupled receptor trafficking for their role in GLP-1R potentiation of insulin secretion in pancreatic β-cells. We identify five (clathrin, dynamin1, AP2, sorting nexins [SNX] SNX27, and SNX1) that increase and four (huntingtin-interacting protein 1 [HIP1], HIP14, GASP-1, and Nedd4) that decrease insulin secretion from murine insulinoma MIN6B1 cells in response to the GLP-1 analog exendin-4. The roles of HIP1 and the endosomal SNX1 and SNX27 were further characterized in mouse and human β-cell lines and human islets. While HIP1 was required for the coupling of cell surface GLP-1R activation with clathrin-dependent endocytosis, the SNXs were found to control the balance between GLP-1R plasma membrane recycling and lysosomal degradation and, in doing so, determine the overall β-cell incretin responses. We thus identify key modulators of GLP-1R trafficking and signaling that might provide novel targets to enhance insulin secretion in T2D.
Keyphrases
- type diabetes
- endothelial cells
- induced apoptosis
- total hip arthroplasty
- cardiovascular disease
- cell cycle arrest
- cell surface
- cell death
- stem cells
- genome wide
- transcription factor
- metabolic syndrome
- gene expression
- bone marrow
- small molecule
- cell proliferation
- mesenchymal stem cells
- drug delivery
- high throughput
- insulin resistance
- skeletal muscle
- adipose tissue
- cancer therapy
- pi k akt